The Schistosomiasis Market was valued at US$ 1.3 Billion in 2025 and is projected to reach US$ 2.07 Billion by 2034, registering a CAGR of 5.29% during 2026–2034. Schistosomiasis is a parasitic disease caused by infection with Schistosoma species and remains an important public-health concern in endemic regions. The market includes pharmaceuticals, diagnostic approaches, and treatment solutions used to manage schistosomiasis. Continued disease burden, public-health programs, improvements in diagnosis, and efforts to expand access to treatment are supporting market development.
What is driving the market?
The persistent prevalence of schistosomiasis in endemic areas and continued demand for effective antiparasitic treatment are major factors driving the Schistosomiasis Market. Transmission is closely associated with exposure to freshwater environments containing infected parasite-host snails, creating a continuing need for disease prevention, diagnosis, and treatment in affected communities.
Get a Sample PDF- https://www.theinsightpartners.com/sample/TIPRE00008459
The market is also supported by large-scale disease-control initiatives and efforts to improve access to essential medicines. Treatment programs focused on at-risk populations can generate sustained demand for antischistosomal therapies. Increasing awareness of neglected tropical diseases and greater investment in healthcare infrastructure and disease surveillance are further contributing to market growth.
Which region leads?
Africa represents a major market for schistosomiasis treatment because of the substantial disease burden across several endemic countries. Public-health agencies, governments, international organizations, and pharmaceutical suppliers play an important role in supporting treatment campaigns and improving access to medicines.
Asia Pacific is another important region, with schistosomiasis remaining relevant in selected endemic areas. Improvements in healthcare infrastructure, diagnostic capacity, sanitation, and disease-control programs are supporting treatment and prevention efforts. Latin America also contributes to market demand, while investments in disease surveillance and public-health interventions can create additional opportunities in endemic communities.
Which segment leads?
Antiparasitic treatment represents the central segment of the Schistosomiasis Market, with praziquantel playing an important role in the treatment landscape. The market can be segmented according to treatment type, disease type, route of administration, distribution channel, and end user.
Treatment programs may target different forms and stages of schistosomiasis depending on the affected population and clinical requirements. Oral treatment is particularly important for large-scale administration and routine disease management. Hospitals, clinics, pharmacies, public-health programs, and community-based healthcare facilities represent important channels for delivering medicines to affected populations.
Which companies are prominent?
Companies in the Schistosomiasis Market are focusing on antiparasitic drug development, manufacturing capacity, treatment accessibility, and pharmaceutical distribution. The market profiles industry participants, including:
- Shin Poong Pharma Co., Ltd.
- Merck & Co., Inc.
- Bayer AG
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Pfizer Inc.
- Sanofi
- Johnson & Johnson
- GlaxoSmithKline plc
- Eli Lilly and Company
- Cipla Limited
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
- Dr. Reddy’s Laboratories Ltd.
- Zydus Lifesciences Limited
- Ipca Laboratories Ltd.
- Alvizia Healthcare Pvt. Ltd.
- Takeda Pharmaceutical Company Limited
- AstraZeneca plc
These companies are analyzed based on competitive strategies and innovation developments. Market participants are focusing on pharmaceutical production, treatment availability, research activities, and partnerships that can support the management of parasitic diseases in endemic and high-risk populations.
What is changing in 2026?
The Schistosomiasis Market is increasingly emphasizing accessible treatment, improved disease surveillance, and integrated approaches to controlling transmission. Public-health programs continue to focus on identifying and treating infected populations while strengthening prevention measures in communities where transmission remains persistent.
Research into new antiparasitic compounds and improved treatment strategies is also important because sustained disease control requires effective therapies and reliable access to medicines. Improvements in diagnostic technologies can support earlier identification of infection and help healthcare programs better target treatment interventions. Integration of treatment campaigns with sanitation, health education, and environmental-control measures is also influencing disease-management strategies.
Get Full Copy of This Report @ https://www.theinsightpartners.com/buy/TIPRE00008459
What are the major investment opportunities?
Investment opportunities are emerging across antiparasitic drug development, accessible treatment formulations, diagnostics, disease surveillance, and healthcare infrastructure in endemic regions. Development of therapies that are effective, affordable, easy to administer, and suitable for large-scale treatment programs can address important needs in schistosomiasis control.
Additional opportunities exist in rapid and accessible diagnostic technologies that can support screening and disease monitoring. Pharmaceutical manufacturers can also expand their presence through partnerships with public-health organizations and regional healthcare systems. Investments that combine medicine supply, diagnostic capabilities, disease surveillance, and community-based healthcare delivery may further support market development through 2034.
Related Reports:
Antiparasitic Market Share, Demand & Growth by 2034
Neglected Tropical Diseases Drugs and Vaccines Market Analysis and Forecast by Size, Share, Growth, Trends 2031
About Us
The Insight Partners is a leading market research and consulting firm delivering actionable insights through in-depth industry analysis and strategic intelligence. The firm supports clients across various industries in making informed business decisions by providing comprehensive market forecasts, competitive assessments, and growth opportunities.
Contact Us
The Insight Partners
Email: sales@theinsightpartners.com
Phone: +1-646-491-9876
Website: www.theinsightpartners.com
Also Available in: Korean German Japanese French Chinese Italian Spanish
